Screening and detection of pancreatic cancer

Journal of the Pancreas

Volumn 12, Issue 4, 2011, Pages 322-324

  Gonda, Tamas A ^a   Lucas, Aimee ^a   Saif, Muhammad Wasif ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Familial; Mass Screening; Pancreatic carcinoma; Pancreatic Neoplasms; Proteomics

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; EPIGENETICS; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PANCREAS CANCER; PANCREATITIS; PEUTZ JEGHERS SYNDROME; PROTEOMICS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

CHICAGO; CONGRESSES AS TOPIC; EARLY DIAGNOSIS; HUMANS; ILLINOIS; MASS SCREENING; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 79960256366     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6(12):699-708.
2. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis 2010;28(4-5):645-656.
3. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56(10):1460-1469.
4. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139(4):1076-1080, 1080 e1071-1072.
5. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009;8(13):2005-2013.
6. Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Wilson S, Moore MJ, et al. Screening for pancreatic cancer in a high-risk cohort: A 7-year experience. J Clin Oncol 2011; 29(Suppl.):4045.
7. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004;1(3):e65.
8. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64(7):2634-2638.
9. Larghi A, Verna EC, Lecca PG, Costamagna G. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 2009;15(6):1907-1914.
10. Wehr AY, Blair IA, Yu KH Tumor microenvironment derived biomarkers for the early detection of pancreatic cancer (PDAC). J Clin Oncol 2011; 29(Suppl.):e14591.
11. Gonda TA, Varro A, Wang TC, Tycko B. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anticancer therapy? Semin Cell Dev Biol 2010;21(1):2-10.
12. Masanume A, Watanabe T, Kikuta K et al. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastro Hepatology 2009; 7:S48-S54.
13. Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas 2011; 40(4):557-566.
14. Everley PA, Krijgsveld J, Zetter BR, Gygi SP. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 2004;3(7):729-735.
15. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002;1(5):376-386.
16. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 2010;56(2):212-222.
17. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131(4):247-255.
18. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. Jul 2004;2(7):606-621.
19. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58(10):1410-1418.
20. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010;16(20):5028-5037.
21. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. May 2011;106(5):946-954.